Bio Cryst - BCRX



Latest 1 day change: BCRX +4.64%

Breaking News

Press Releases




About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. 
RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S.CanadaAustraliaJapanTaiwanKorea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.









Email Publisher@YWPNNN.com



Comments

Marketing Business Networking Deal

IssueWire | Press Release Distribution - Yvonne Wilcox Pen Name

LHMPR Radio

Anchor FM

Blog Talk Radio

Popular Posts